LOS ANGELES, CA / ACCESSWIRE / December 1, 2016 / Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that Company management will be presenting at the 9th annual LD Micro Main Event on Tuesday, December 6th at 11:30 AM PST (2:30 PM EST) at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will be presenting a corporate overview, as well as meeting with investors.
The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names.
Mr. Berlin's presentation will be webcast live and archived for 90 days on the Company's website at www.rosettagx.com.
View Rosetta Genomics' profile here: http://www.ldmicro.com/profile/ROSG
News Compliments of Accesswire.
About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company now offers core FISH, IHC, and PCR-based testing capabilities and partnerships in Pathology, Oncology, and Urology that provide additional content and platforms that complement Rosetta's microRNA and Next-Gen Sequencing offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of indeterminate thyroid FNA smears, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company's Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs. For more information visit www.rosettagx.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
Rosetta Genomics Contact:
Ken Berlin, President & CEO
(267) 298-1159
investors@rosettagx.com
Rosetta Genomics Investor Contact:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com
SOURCE: Rosetta Genomics vid LD Micro
ReleaseID: 450072
